John Oyler, BeiGene CEO (Endpoints News, PharmCube)
July 20, 2020 08:10 AM EDT
Deals

BeiGene ex­pands pipeline and hops on board a quest to cure hep B, ink­ing a $540M deal with a fel­low up­start biotech

John Carroll

Editor & Founder

Chi­na biotech BeiGene $BGNE is step­ping up with $40 mil­lion in cash and $500 mil­lion for a smor­gas­bord of mile­stones to part­ner with up­start As­sem­bly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times